Protecting Care Between Visits: How the 2027 CMS Rule Preserves Remote Diabetes Monitoring


Continuous glucose monitors (CGMs) are transforming diabetes management, paving the way for far more proactive, data-driven care. By delivering real-time data to both patients and their care teams, CGMs are helping patients stay connected and supported between routine visits.
When CMS released the CY 2027 Physician Fee Schedule final rule on November 4, 2026, the bottom line for continuous and remote care was encouraging: Medicare continues to value the clinical work that happens between visits for chronic conditions like diabetes. With this rule, CMS made it clear that supporting high-quality remote monitoring for high-need patients remains a priority.
Here is a look at the key updates, how they strengthen remote care for diabetes, and how your practice can navigate the road ahead.
While the CMS final rule focuses specifically on remote patient monitoring (RPM) between routine visits, practices have several other pathways to provide continuous remote care for patients with diabetes. Learn more about how different practices are offering remote care for their patients from our recent webinar.
1. Initiating Visits: Building Enrollment Around Trust and Clinical Need
Starting January 1, 2027, patients enrolling in RPM must first discuss remote monitoring with their billing practitioner (or a same-specialty colleague in the same clinic) during a face-to-face visit, either in person or via telehealth.
This policy simply reaffirms what high-performing remote care programs already know: the most effective patient enrollment revolves around a clinically-driven conversation with a trusted provider.
This approach ensures two critical outcomes:
The program is introduced specifically to patients with a clear clinical need for more regular monitoring
Patients leave the discussion with a thorough understanding of what the program entails, why they are a good fit, and the clinical benefits of participating in the program.
(A high-touch enrollment model is essential not only for obtaining program consent, but for ensuring that patients stay engaged in the program over time.)
Identifying clinical need is a key component for a successful RPM program, which can be difficult to accomplish across an entire patient population without a centralized view of all patient device data.
With SweetSpot, practices can view all their patients’ data from every major device in one place and triage those who would benefit most from an RPM program. Once enrolled, our dashboard tracks program consent, logged remote care events, and the appropriate CPT billing codes.
In a recent SweetSpot webinar, our team walked through a case study from an endocrinology practice utilizing our platform to identify patients for its in-house RPM program based on clinical need. Read the recap here.
Details to Note About the Initiating Visit Requirement:
CMS designed the initiating visit requirement with practitioner flexibility in mind to keep these care pathways open:
Routine Diabetes Visits Qualify: There is no need to schedule a separate, dedicated RPM appointment. A standard Evaluation & Management (E/M) routine diabetes follow-up where remote monitoring is brought up and documented satisfies the rule.
No Expiration Clock: There is no required window or deadline between the initial discussion and the official start of remote monitoring, such as signing a consent form.
One and Done: The visit requirement is a one-time step per patient. Updating care plans, adjusting devices, or seeing a new provider within the same practice will not trigger a reset.
Current Patients Stay Enrolled: Existing patients actively receiving remote diabetes care prior to January 1, 2027, are grandfathered in and do not need a retrospective visit.
2. Third-Party Clinical Support: Delayed to 2029 (and How You Can Already Plan Ahead)
One of the most talked-about CMS proposals, limiting RPM treatment management billing exclusively to direct employees of the practice, has been officially delayed until 2029.
In CMS rulemaking, a two-year delay often signals that the final rule could be revised, extended, or dropped entirely. Still, forward-thinking endocrinology practices don't need to wait to implement strategies that protect long-term compliance and program success.
Why Partnering with SweetSpot Makes Sense Today:
Immediate Clinical Scale with Zero Staffing Burden: For 2027–2028, CMS explicitly permits contracted clinical support under incident-to supervision. Partnering with us gives your practice a team of expert diabetes care specialists to manage continuous CGM data and patient touchpoints without adding administrative overhead to your clinic.
Strategic Regulatory Protection: We stay ahead of evolving CMS rules so you don’t have to, guiding your team to ensure your program continuously meets requirements and runs smoothly. We also support multiple unaffected code sets alongside RPM.
Flexible, Future-Proof Roadmap: Whether you want us to handle remote monitoring indefinitely or eventually transition management in-house down the road, we design scalable workflows tailored to your practice size. You get the benefits of an expert partner today and total flexibility for whatever 2029 brings.
3. Code Values Reflect the Core Importance of Clinical Work
The final change we’d like to highlight is how the 2027 financial structure for remote monitoring reflects a clear recognition of the clinical time required to provide high-quality care:
Treatment Management Holds Its Ground: CPT codes 99457, 99458, and 99470 (which compensate clinical staff for ongoing patient engagement, reviewing glucose trends, and providing care between visits) maintained their value. CMS withdrew previously proposed cuts after recognizing that clinical interaction between visits is the heart of effective remote care.
Device and Setup Adjustments: Rates for setup and monthly device transmission (CPT 99453, 99454, and 99445) will see phased adjustments over 2027 and 2028. CMS explicitly noted a current lack of comprehensive cost data and wrote that it will work with healthcare stakeholders to gather input for potential increases in 2028.
The Big Picture: Care Between Visits Is Here to Stay
Looking beyond reimbursement updates, the 2027 final rule reaffirms CMS’s ongoing commitment to RPM for chronic conditions like diabetes. The takeaway for providers is clear: CMS continues to recognize the value of consistent, data-driven support between appointments in helping patients successfully manage their health.
By bringing remote diabetes care discussions naturally into office visits and structuring your RPM program around clinical need, your clinic can continue delivering high-value care. Working alongside a partner who keeps a close pulse on regulatory shifts and offers flexible program design ensures you can move forward with full confidence in the year ahead and beyond.
Want to explore how remote diabetes monitoring can fit into your practice? Connect with our team at info@sweetspot.health for a quick discussion on getting the most out of care between visits while remaining complaint and financially sustainable.
-------
SweetSpot partners with endocrinology practices to deliver proactive care between visits.
The SweetSpot platform brings every patient’s CGM and pump data from all major devices into one dashboard. From there, practices can review patient data, triage patients by clinical need, schedule additional visits, and run remote patient monitoring (RPM) and chronic care management (CCM) programs, with care time and billing tracked automatically. SweetSpot’s Certified Diabetes Care and Education Specialists (CDCESs) act as an extension of the practice’s team, supporting as much or as little of the program as each practice chooses. Learn more at www.sweetspot.health.



Comments